TIL the hot topic in novel anti-tumour therapy at ASCO 2019

With early results showing promising efficacy in patients with advanced refractory melanoma, adoptive cell therapy (ACT) using tumour infiltrating lymphocytes (TIL) proved to be one of the main talking points of ASCO 2019. In a session entitled “Beyond Checkpoint Blockade” Dr Stephanie Goff of the  NIH-National Cancer Institute-Center for cancer Research explained that the ACT ...